selected scholarly activity
-
conferences
- Case series of multiple myeloma and kidney transplant outcome: Clinical characteristics and long-term follow-up. Transplantation. 558-558. 2024
- Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.. Journal of Clinical Oncology. 2023
- Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study. Blood. 9383-9384. 2022
- Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood. 10111-10113. 2022
- Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry. Blood. 6-7. 2020
- The role of bone marrow biopsy in patients with plasma cell disorders; should all patients with a monoclonal protein be biopsied?. Clinical Lymphoma, Myeloma and Leukemia. e333-e333. 2019
- Venetoclax For The Treatment of Translocation AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia. e332-e332. 2019
-
journal articles
- Are we maintaining minimal residual disease in myeloma?. Leukemia and Lymphoma. 66:1001-1009. 2025
- FIXED DURATION TREATMENT OF BENDAMUSTINE‐RITUXIMAB AND ACALABRUTINIB IN FRONTLINE WALDENSTROM’S MACROGLOBULINEMIA: DEEP MOLECULAR RESPONSES IN HIGH‐RISK PATIENT SUBSETS. Hematological Oncology. 43. 2025
- Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research. Blood. 144:19271-19273. 2024
- Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenstrom's Macroglobulinaemia That Induce Deep Clinical Responses. Blood. 144:6291-6292. 2024
- Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 144:703-704. 2024
- Case series of multiple myeloma and kidney transplant outcome: Clinical characteristics and long-term follow-up.. Transplantation. 108. 2024
- Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL). Leukemia and Lymphoma. 65:1167-1174. 2024
- A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial. Journal of Geriatric Oncology. 15:101735-101735. 2024
- Efficacy of Maintenance Therapies By Prognostic Subgroups in Post-Transplant Newly Diagnosed Multiple Myeloma Patients: A Systematic Review and Network Meta-Analysis. Blood. 142:3348-3348. 2023
- Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM). Blood. 142:3037-3037. 2023
- Monoclonal Immunoglobulin Deposition Disease - a Review of Current and Emerging Data. Blood. 142:6757-6757. 2023
- Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:3774-3774. 2023
- Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis. Journal of Geriatric Oncology. 14:101592-101592. 2023
- Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leukemia Research. 131:107324-107324. 2023
- Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.. Journal of Clinical Oncology. 41:e24078-e24078. 2023
- Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM). Hematological Oncology. 41:396-397. 2023
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplantation. 58:478-490. 2023
- Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials. Cancer. 128:2288-2297. 2022
- Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises. Cancers. 14:113-113. 2021
- Choosing optimal therapy for relapsed refractory multiple myeloma: A systematic review and network meta-analysis.. Journal of Clinical Oncology. 39:e20037-e20037. 2021
- Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal. 10:55. 2020
- The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal. 10:52. 2020
- The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. Acta Haematologica. 143:118-123. 2020
- Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation. 54:1077-1081. 2019
- PF625 VENETOCLAX FOR THE TREATMENT OF TRANSLOCATION (11; 14) AL AMYLOIDOSIS. HemaSphere. 3:265-266. 2019
- Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances. 3:1226-1229. 2019
- Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation. 54:442-447. 2019
- T-cell large granular lymphocytic leukemia and plasma cell disorders. Haematologica. 104:e108-e110. 2019
- Therapy for relapsed multiple myeloma. Panminerva Medica. 60:174-184. 2018
- Utility and prognostic value of 18F‐FDG positron emission tomography‐computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology. 93:1518-1523. 2018
- Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood. 132:2147-2147. 2018
- Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood. 132:3182-3182. 2018
- Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood. 132:3160-3160. 2018
- T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. Blood. 132:5368-5368. 2018
- Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood. 132:3436-3436. 2018
- Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances. 2:3149-3154. 2018
- Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal. 8:106. 2018
- Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Transplantation and Cellular Therapy. 24:2360-2364. 2018
- Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Transplantation and Cellular Therapy. 24:2157-2159. 2018
- Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica. 103:1229-1234. 2018
- Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology. 36:8023-8023. 2018
- Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology. 36:1323-1329. 2018
- Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances. 2:769-776. 2018
- Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Medicine. 4:864-870. 2015
- Effect of dose intensification (DI) of octreotide-LAR (O-LAR) among symptomatic patients with neuroendocrine tumors (NETs).. Journal of Clinical Oncology. 32:299-299. 2014
- Strongyloides stercoralis hyperinfection in a post-renal transplant patient. Clinical and Experimental Gastroenterology. 4:269-269. 2011
- Thromboembolism in inflammatory bowel diseases: a report from Saudi Arabia. Clinical and Experimental Gastroenterology. 4:1-1. 2011
- The Impact of COVID-19 on Cyber Security. International Journal of Computer Trends and Technology. 69:38-40.